Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Bio-Path Holdings, Inc. develops RNA interference (RNAi) nanoparticle therapeutics using its proprietary DNAbilize® platform, which delivers antisense DNA drugs systemically to inhibit disease-causing proteins. Focused on oncology and metabolic diseases, its pipeline targets cancers such as acute myeloid leukemia, lymphoma, pancreatic, and solid tumors, as well as obesity-related conditions. The company advances drug candidates through clinical trials and leverages partnerships for development, manufacturing, and commercialization.
This description was generated via AI from an annual report. Updated about 1 year ago.